By providing information about the prevalence and dynamics of vaccine antigen polymorphisms in a population being targeted for malaria vaccines, this study will inform choices about which MSP-119 haplotypes to include in future vaccine formulations, and will allow more accurate interpretation of the efficacy of current formulations of MSP-1–based vaccines being tested in clinical trials. The gene discussed is ATAD1; the disease is malaria.